Artugen Announces Oral and Poster Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases

Clostridioides difficile infection (CDI) causes the most common healthcare-associated infections in the United States and the most frequent hospital-acquired intestinal infection in Europe and worldwide. The prevalence of C. difficile outbreaks since the early 2000s has resulted in higher morbidity and mortality along with increasing medical costs throughout the world.

Without effective antibiotics and therapeutics for the prevention and treatment of infections, many of the achievements of modern medicine such as organ transplantations, chemotherapy and surgeries such as caesarean sections become much more dangerous.

The Artugen team has discovered and is developing a novel oral Live Biotherapeutic Product for the prevention of C. difficile infection recurrence.

Oral presentation

TITLE: ART24, a novel live biotherapeutic product, in development for the prevention of Clostrioides difficile infection spares gut commensal species in vitro and allows for expansion of beneficial bacteria. Michelle O’Donnell et al., #O0994

SESSION: New drugs and new targets for highly resistant bacteria

More information

Posters

TITLE: ART24, a novel live biotherapeutic product, in development for the prevention of Clostrioides difficile infection is bactericidal against C. difficile and degrades toxins A and B in vitro. James Hegarty et al., #P1508

TITLE: ART24, a novel live biotherapeutic product, in development for the prevention of Clostrioides difficile infection is active against a broad range of C. difficile ribotypes in vitro. James Hegarty et al.; #P1507

TITLE: ART24, a novel live biotherapeutic product, in development for the prevention of Clostrioides difficile infection (CDI) recurrence is effective in a mouse model of CDI infection. Laurent Chesnel et al.; #P1506

TITLE: Safety characterisation of ART24, a novel live bio-therapeutic product, in development for the prevention of Clostridiodes difficile infection, by in silico and in vitro testing. Michelle O’Donnell et al.; #P1536

SESSION: New Antibacterial Agents, PK/PD & Stewardship

More information